Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.02 per share a year ago.

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s ...

The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 52 cents per share. The drugmaker posted revenue of $174.2 million in the period, which also beat ...

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...

Reports Q4 revenue $174.2M, consensus $155.25M. “Our 2024 results reflect solid commercial execution across the company, including continued ...

The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...